基本信息
电子邮件:zhmiao@simm.ac.cn
手机号码:
通信地址:
邮政编码:

研究领域

肿瘤药理学。从事抗肿瘤新药研究研发及抗肿瘤作用机制研究,着重在细胞和分子水平围绕肿瘤的缺氧应答、DNA损伤修复、耐药及三者间内在联系展开抗肿瘤干预研究。

招生信息

   
招生专业
100706-药理学
招生方向
肿瘤药理学

教育背景

2004.10---2006.9 Laboratory of Molecular Pharmacology, Center for Cancer Research, NCI, NIH, USA, Visiting Fellow
2000.9---2003.7 博士研究生,中国科学院上海药物研究所, 药理学专业,2003年7月毕业,获理学博士学位。
1993.9---1996.7 硕士研究生, 中国医学科学院中国协和医科大学肿瘤研究所,药理学专业;1996年7月毕业,获医学硕士学位。
1982.9---1988.7 本科(六年制), 华西医科大学医学专业, 毕业获医学学士学位。

学历
-- 研究生
学位
-- 博士

工作经历

2003.7 至今 中国科学院上海药物研究所肿瘤药理实验室, 副研究员、研究员、博士研究生导师、课题组长。 
1988.7---2000.8 四川泸州医学院药理教研室,药理学助教、讲师、副教授。

工作简历
2004-10--2006-09 美国国立卫生研究院国家癌症研究所(NCI, NIH) Visiting Fellow
2003-07--2011-06 中国科学院上海药物研究所 副研究员、研究员、博士生导师、课题组长
1988-07--2000-08 四川泸州医学院 助教、讲师、副教授、教研室副主任

教授课程

高等药理学

获奖与荣誉

1. 国家杰出青年基金获得者(2010)
2. 国家自然科学奖二等奖(2009)
3. 药明康德生命化学研究奖三等奖(2009)
4. 入选上海市浦江人才计划(2008)
5. 上海市自然科学奖一等奖(2007)
6. 全国百篇优秀博士论文奖(2005)
7. 中国科学院院长特别奖(2004)
8. 中国科学院优秀博士学位论文(2004)
9. 上海药学科技一等奖(2004)
10. 中国药理学会Servier奖(2003)
奖励信息
(1) 拓扑异构酶II新型抑制剂沙尔威,二等奖,国家级,2009
(2) 转录因子c-Jun抑制mdr-,三等奖,其他级,2009
(3) 抗肿瘤新药分子药理作用机制研究,一等奖,省级,2007
(4) 沙尔威辛抗肿瘤多药耐药分子机制,国家级,2005
专利成果
(1) 毛红椿苦素及其制备方法和用途,发明,2010,第4作者,专利号:201010216708.2
(2) 一种测定人或动物全血中希明替康和吉咪替康的方法,发明,2010,第5作者,专利号:201010260758.0
(3) 棕榈菌素BG5及其制备方法和用途,发明,2010,第2作者,专利号:201010272157.1
(4) 一类新型咪唑类化合物及其用途,发明,2010,第2作者,专利号:201010238260.4
(5) 一种具有1,12-二烯-3-酮骨架的甘草次酸衍生物、其制备方法及医药用途,发明,2011,第3作者,专利号:CN201110131028.5
(6) 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途,发明,2012,第2作者,专利号:201210028895.0

出版信息

   
发表论文
[1] An, Weiteng, Wang, Wei, Yu, Ting, Zhang, Yongliang, Miao, Zehong, Meng, Tao, Shen, Jingkang. Discovery of novel 2-phenyl-imidazo1,2-apyridine analogues targeting tubulin polymerization as antiproliferative agents. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY[J]. 2016, 112: 367-372, http://dx.doi.org/10.1016/j.ejmech.2016.02.004.
[2] Wang, YingQing, Wang, PingYuan, Wang, YuTing, Yang, GuangFu, Zhang, Ao, Miao, ZeHong. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy. JOURNAL OF MEDICINAL CHEMISTRY[J]. 2016, 59(21): 9575-9598, https://www.webofscience.com/wos/woscc/full-record/WOS:000387737600001.
[3] Yi, JunMei, Huan, XiaJuan, Song, ShanShan, Zhou, Hu, Wang, YingQing, Miao, ZeHong. Triptolide Induces Cell Killing in Multidrug-Resistant Tumor Cells via CDK7/RPB1 Rather than XPB or p44. MOLECULAR CANCER THERAPEUTICS[J]. 2016, 15(7): 1495-1503, https://www.webofscience.com/wos/woscc/full-record/WOS:000381087200007.
[4] Jiang, Xue, Wang, Meining, Song, Shanshan, Xu, Youjun, Miao, Zehong, Zhang, Ao. Design, synthesis, and anticancer activities of new compounds bearing the quinone-pyran-lactone tricyclic pharmacophore. RSC ADVANCES[J]. 2015, 5(35): 27502-27508, https://www.webofscience.com/wos/woscc/full-record/WOS:000351556100040.
[5] Yan Wang, JiaXin Li, YingQing Wang, ZeHong Miao. Tanshinone I inhibits tumor angiogenesis by reducing STAT3 phosphorylation at TYR705 and hypoxia-induced HIF-1α accumulation in both endothelial and tumor cells. ONCOTARGET. 2015, 6(18): 16031-16042, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599254/.
[6] 缪泽鸿. RhIII-Catalyzed Redox-Neutral C-H Activation of Pyrazolones: An Economical Approach for Synthesis of N-Substituted Indoles. Org Lett. 2015, [7] JunMei Yi, XiaoFei Zhang, XiaJuan Huan, ShanShan Song, Wei Wang, QianTing Tian, YiMing Sun, Yi Chen, Jian Ding, YingQing Wang, ChunHao Yang, ZeHong Miao. Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition. ONCOTARGET. 2015, 6(11): 8960-8973, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496195/.
[8] Zhao, Lele, Wang, Yingqing, Cao, Danyan, Chen, Tiantian, Wang, Qi, Li, Yanlian, Xu, Yechun, Zhang, Naixia, Wang, Xin, Chen, Danqi, Chen, Lin, Chen, YueLei, Xia, Guangxin, Shi, Zhe, Liu, YuChih, Lin, Yijyun, Miao, Zehong, Shen, Jingkang, Xiong, Bing. Fragment-Based Drug Discovery of 2-Thiazolidinones as BRD4 Inhibitors: 2. Structure-Based Optimization. JOURNAL OF MEDICINAL CHEMISTRY[J]. 2015, 58(3): 1281-1297, https://www.webofscience.com/wos/woscc/full-record/WOS:000349573800020.
[9] Li, JX, Feng, JM, Wang, Y, Li, XH, Chen, XX, Su, Y, Shen, YY, Chen, Y, Xiong, B, Yang, CH, Ding, J, Miao, ZH. The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. CELL DEATH & DISEASE[J]. 2014, 5(6): e1278-, https://www.webofscience.com/wos/woscc/full-record/WOS:000338778500006.
[10] 缪泽鸿. Natrual product-based design, synthesis and biological evaluation of anthra[2,1-d]thiazole-6,11-dione derivatives from rhein as novel antitumour agents. Eur J Med Chem. 2014, [11] Li, Bo, Yue, Zhizhou, Xiang, Haoyue, Lv, Linlin, Song, Shanshan, Miao, Zehong, Yang, Chunhao. Catalyst-free synthesis of benzofuran-fused pyrido 4,3-dpyrimidines from 2-(2-hydroxyaryl)acetonitrile and 4,6-dichloropyrimidine-5-carbaldehyde through domino condensation reactions. RSC ADVANCES[J]. 2014, 4(1): 358-364, https://www.webofscience.com/wos/woscc/full-record/WOS:000327547000047.
[12] Wang, Wei, Wang, YingQing, Meng, Tao, Yi, JunMei, Huan, XiaJuan, Ma, LanPing, Tong, LinJiang, Chen, Yi, Ding, Jian, Shen, JingKang, Miao, ZeHong. MCL-1 Degradation Mediated by JNK Activation via MEKK1/TAK1-MKK4 Contributes to Anticancer Activity of New Tubulin Inhibitor MT189. MOLECULAR CANCER THERAPEUTICS[J]. 2014, 13(6): 1480-1491, https://www.webofscience.com/wos/woscc/full-record/WOS:000337168600009.
[13] 缪泽鸿. Synthesis of isoquinolinone-based tricycles as novel poly(ADP-ribosyl) polymerase-1 (PARP-1) inhibitors. Bioorg Med Chem Lett. 2014, [14] 缪泽鸿. Rapid Access to α-Carbolines via a One-pot Tandem Reaction of α, β-Unsaturated Ketones with 2-Nitrophenylacetonitrile and the Bioactivities of the Products. Org Biomol Chem. 2014, [15] Meng, Tao, Wang, Wei, Zhang, Zhixiang, Ma, Lanping, Zhang, Yongliang, Miao, Zehong, Shen, Jingkang. Synthesis and biological evaluation of 6H-pyrido2 ',1 ':2,3 imidazo4,5-c isoquinolin-5(6H)-ones as antimitotic agents and inhibitors of tubulin polymerization. BIOORGANIC & MEDICINAL CHEMISTRY[J]. 2014, 22(2): 848-855, http://dx.doi.org/10.1016/j.bmc.2013.12.004.
[16] 缪泽鸿. The inhibition of metastasis and growth of breast cancer by blocking the NF-kB signaling pathway using bioreducible PEI-based/p65 shRNA complex nanoparticles. Biomaterials. 2013, [17] 缪泽鸿. Design and synthesis of pyrido[3,2-a]carbazole derivatives and their analogues as potent antitumor agents.. Eur J Med Chem. 2013, [18] YingQing Wang. Marine-Derived Angiogenesis Inhibitors for Cancer Therapy. MDPI. 2013, http://oa.las.ac.cn/oainone/service/browseall/read1?ptype=JA&workid=JA202003190037798ZK.
[19] Xu, L, Feng, JM, Li, JX, Zhu, JM, Song, SS, Tong, LJ, Chen, Y, Yang, XY, Shen, YY, Lian, FL, Li, YP, Lin, DH, Ding, J, Miao, ZH. Tanshinone-1 induces tumor cell killing, enhanced by inhibition of secondary activation of signaling networks. CELL DEATH & DISEASE[J]. 2013, 4: https://www.webofscience.com/wos/woscc/full-record/WOS:000327760500003.
[20] 缪泽鸿. Design, synthesis and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8h)-ones bearing a longer chain as novel PARP1 inhibitors. J Med Chem. 2013, [21] Manzo, Stefano Giustino, Zhou, ZhaoLi, Wang, YingQing, Marinello, Jessica, He, JinXue, Li, YuanChao, Ding, Jian, Capranico, Giovanni, Miao, ZeHong. Natural Product Triptolide Mediates Cancer Cell Death by Triggering CDK7-Dependent Degradation of RNA Polymerase II. CANCER RESEARCH[J]. 2012, 72(20): 5363-5373, http://dx.doi.org/10.1158/0008-5472.CAN-12-1006.
[22] 缪泽鸿. The Conversion Between the CD133+ Cells and the CD133- Cells in the Colon Cancer SW620 Cell Line. Cancer Biol Ther. 2012, [23] Jin-xue HE Ying-qing WANG Jian-ming FENG Jia-xin LI Lei XU Xiao-hua LI Wei WANG Xia-juan HUAN Yi JIANG Bing YU Guang CHEN Ze-hong MIAO. Differential sensitivity of RIP3-proficient and deficient murine fibroblasts to camptothecin anticancer drugs. 中国药理学报:英文版[J]. 2012, 33(3): 426-428, http://lib.cqvip.com/Qikan/Article/Detail?id=41240132.
[24] Zhou, ZhaoLi, Yang, YaXi, Ding, Jian, Li, YuanChao, Miao, ZeHong. Triptolide: structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms. NATURAL PRODUCT REPORTSnull. 2012, 29(4): 457-475, https://www.webofscience.com/wos/woscc/full-record/WOS:000301455600003.
[25] Yu, Bing, Li, MeiHong, Wang, Wei, Wang, YingQing, Jiang, Yi, Yang, ShengPing, Yue, JianMin, Ding, Jian, Miao, ZeHong. Pseudolaric acid B-driven phosphorylation of c-Jun impairs its role in stabilizing HIF-1alpha: a novel function-converter model. JOURNAL OF MOLECULAR MEDICINE-JMM[J]. 2012, 90(8): 971-981, https://www.webofscience.com/wos/woscc/full-record/WOS:000306437700011.
[26] 缪泽鸿. Design, synthesis and biological evaluation of substituted 11H-benzo[a]carbazole-5-carboxamide as novel antitumor agents.. 2011, [27] 缪泽鸿. Echinoside A, a new marine-derived anticancer saponin, targets topoisomerase II? by unique interference with its DNA binding and catalytic cycle.. Ann Oncol. 2010, [28] 缪泽鸿. MFTZ-1, a novel topoisomerase II poison, reduces constitutive and inducible HIF-1α accumulation and VEGF secretion irrelevant to its topoisomerase II inhibition.. 2010, [29] Zhang, Zhixiang, Meng, Tao, He, Jingxue, Li, Ming, Tong, LinJiang, Xiong, Bing, Lin, Liping, Shen, Jingkang, Miao, ZeHong, Ding, Jian. MT7, a novel compound from a combinatorial library, arrests mitosis via inhibiting the polymerization of microtubules. INVESTIGATIONAL NEW DRUGS[J]. 2010, 28(6): 715-728, http://ir.simm.ac.cn/handle/153631/1923.
[30] 缪泽鸿. PARP inhibitors as promising cancer therapeutics. Acta Pharmacol Sin. 2010, [31] Zhou, ZhaoLi, Luo, ZhiGuo, Yu, Bing, Jiang, Yi, Chen, Yi, Feng, JianMing, Dai, Mei, Tong, LinJiang, Li, Zheng, Li, YuanChao, Ding, Jian, Miao, ZeHong. Increased accumulation of hypoxia-inducible factor-1 alpha with reduced transcriptional activity mediates the antitumor effect of triptolide. MOLECULAR CANCER[J]. 2010, 9: http://ir.simm.ac.cn/handle/153631/1933.
[32] 缪泽鸿. Naphthalimides induce G2 phase arrest in HCT-116 cells via ATM-activated Chk2-executed pathway.. Neoplasia. 2009, [33] 缪泽鸿. c-Jun protects HIF-1? from degradation via its Oxygen-Dependent-Degradation domain in a non-transcriptional manner.. 2009, [34] 缪泽鸿. Non-Classical Functions of Human Topoisomerase I:Genomewide and Pharmacological Analyses.. Cancer Res. 2007, [35] 缪泽鸿. Defective repair of topoisomerase I cleavage complexes in hereditary ataxia SCAN1 cells.. DNA Repair. 2006, [36] Ding, Jian, Miao, ZeHong, Meng, LingHua, Geng, MeiYu. Emerging cancer therapeutic opportunities target DNA-repair systems. TRENDS IN PHARMACOLOGICAL SCIENCESnull. 2006, 27(6): 338-344, http://dx.doi.org/10.1016/j.tips.2006.04.007.
[37] Miao, ZH, Rao, VA, Agama, K, Antony, S, Pommier, Y. 4-nitroquinoline-1-oxide induces the formation of cellular topoisomerase I-DNA cleavage complexes.. CLINICAL CANCER RESEARCHnull. 2005, 11(24): 9020S-9020S, https://www.webofscience.com/wos/woscc/full-record/WOS:000234382700227.
[38] Miao, ZH, Ding, J. Transcription factor c-Jun activation represses mdr-1 gene expression. CANCER RESEARCH[J]. 2003, 63(15): 4527-4532, https://www.webofscience.com/wos/woscc/full-record/WOS:000184562500035.
[39] Jiang Yi, Miao Ze-Hong, Xu Lei, Yu Bing, Gong Jing-Xu, Tong Lin-Jiang, Chen Yi, Zhou Zhao-Li, Liu Hong-Chun, Wang Yi, Guo Yue-Wei, Ding Jian. Drug Transporter-independent Liver Cancer Cell Killing by a Marine Steroid Methyl Spongoate via Apoptosis Induction *. THE JOURNAL OF BIOLOGICAL CHEMISTRY. 286(30): 26461-26469, http://dx.doi.org/10.1074/jbc.M111.232728.

科研活动

   
科研项目
(1) 抗肿瘤新靶点的研究—RIP3:抗肿瘤分子靶点发现及其化学干预研究,主持,其他级,2012-04--2014-03
(2) 抗肿瘤药物早期成药性评价关键技术研究,主持,国家级,2012-01--2015-12
(3) 新型纳米药物降低肝癌细胞耐药性的机制和药效学研究,主持,国家级,2012-01--2016-08
(4) 新型PARP-1抑制剂的设计优化和成药性研究,参与,国家级,2012-01--2015-12
(5) 抗肿瘤药物药理,主持,国家级,2011-01--2014-12

指导学生

现指导学生

贺金雪  博士研究生  100706-药理学  

陈川惠子  硕士研究生  077906-药理学  

徐磊  博士研究生  100706-药理学  

王炜  博士研究生  100706-药理学  

衣君玫  硕士研究生  077906-药理学  

李佳昕  博士研究生  100706-药理学